Evidence map›Paper›PMID 35385678›Full record

ArticleHuman vaccines & immunotherapeutics2022

Two adolescent cases of acute tubulointerstitial nephritis after second dose of COVID-19 mRNA vaccine.

Jae Hong Choi, Ki-Soo Kang, Kyoung Hee Han

Open access · goldAbstract readCase Reports
In one paragraph

Article in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Renal Complications Following COVID-19 Vaccination: A Narrative Literature Review.Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jae Hong ChoiDepartment of Pediatrics, College of Medicine, Jeju National University, Jeju, Republic of Korea.ORCID 0000-0003-3284-9407
Ki-Soo KangDepartment of Pediatrics, College of Medicine, Jeju National University, Jeju, Republic of Korea.ORCID 0000-0001-6374-8356
Kyoung Hee HanDepartment of Pediatrics, College of Medicine, Jeju National University, Jeju, Republic of Korea.ORCID 0000-0002-6830-7311
Jeju National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Food and Drug Administration (FDA) expanded the emergency use authorization for the BNT162b2 messenger RNA (mRNA) vaccine (Pfizer-BioNTech) for children aged 12-15 years on 10 May 2021. To date, less than a year has passed since vaccination against COVID-19 has been used in children and adolescents, and the overall effects and safety of these vaccines are still being assessed. The BNT162b2 vaccine originally had a favorable profile in 12-17-year-old recipients compared with older ages, and no serious adverse events had previously been reported. Despite various adverse events, the benefit of reducing the infection rate or the frequency of severe COVID-19 has been evaluated to outweigh the harm caused by COVID-19 vaccination. Additionally, several cases of sudden development of new-onset or relapsing glomerular diseases, including acute kidney injury (AKI), have been reported in adults following the BNT162b2 SARS-CoV-2 mRNA vaccine. Herein, we present two cases of adolescents who developed AKI following the second administration of the BNT162b2. These are the first pediatric cases of acute tubulointerstitial nephritis temporarily linked to SARS-CoV-2 vaccination.

Indexed as

BNT162 VaccineCOVID-19Nephritis, InterstitialAdolescentHumansSARS-CoV-2BNT162 VaccineAcute interstitial nephritisadolescentBNT162b2 mRNA Covid-19 vaccinechildCOVID-19pandemics/prevention & controlSARS-CoV-2vaccination

Identifiers

PMID35385678
PMCPMC9897634
OpenAlexW4225556939

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.